

=> d his

(FILE 'HOME' ENTERED AT 17:02:38 ON 25 FEB 2003)

FILE 'REGISTRY' ENTERED AT 17:02:46 ON 25 FEB 2003

L1 149 S C26H30N6O3/MF
 L2 9 S L1 AND 333.151.57/RID
 L3 4 S L2 AND NRS=2 AND NR=4

*searched mol. formula, ring i.d. for indole, no. ring systems = 2, & no. rings = 4
 retrieved 4 compds, 2 of which were stereoisomers matching compd. from claims.*

FILE 'HCAPLUS' ENTERED AT 17:08:14 ON 25 FEB 2003

L4 3 S L3 *retrieved 3 cit's for basic compd.*

FILE 'REGISTRY' ENTERED AT 17:09:38 ON 25 FEB 2003

L5 SCREEN 2127 *created screen for 20 more compds to search for salts*
 L6 *STRUCTURE - created str. from*
 L7 *1 S L5 AND L6*
 L8 *24 S L6 FULL 24 compds*
 L9 *3 S L5 AND L6 FULL 3 compds with salts*
 L10 *STRUCTURE*
 L11 *1 S L10 AND L5*
 L12 *3 S L10 AND L5 FULL*
 L13 *3 S L9 OR L12 & came up with same results*

yield both stereoisomers

FILE 'HCAPLUS' ENTERED AT 17:19:59 ON 25 FEB 2003

L14 1 S L13
 L15 3 S L4 OR L14 *retrieved same cit's as in L4, above.*


*These 3 cit's are appended.
 See "d gene stat" for structure & history
 of search.*

*Please let me know if you would like for
 me to go over these results with you.*

*M. J. Ruhl
 605-1155*

=> d que stat 115

L1 149 SEA FILE=REGISTRY ABB=ON C26H30N6O3/MF
 L2 9 SEA FILE=REGISTRY ABB=ON L1 AND 333.151.57/RID
 L3 4 SEA FILE=REGISTRY ABB=ON L2 AND NRS=2 AND NR=4
 L4 3 SEA FILE=HCAPLUS ABB=ON L3
 L5 SCR 2127
 L6 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L9 3 SEA FILE=REGISTRY SSS FUL L5 AND L6
 L10 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L12 3 SEA FILE=REGISTRY SSS FUL L10 AND L5

L13 3 SEA FILE=REGISTRY ABB=ON L9 OR L12

L14 1 SEA FILE=HCAPLUS ABB=ON L13

L15 3 SEA FILE=HCAPLUS ABB=ON L4 OR L14

=> d ibib abs hitstr 115 1-3

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:774900 HCAPLUS

DOCUMENT NUMBER: 138:66879

TITLE: EP1572: A novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man
AUTHOR(S): Broglio, F.; Boutignon, F.; Benso, A.; Gottero, C.; Prodham, F.; Arvat, E.; Ghe, C.; Catapano, F.; Torsello, A.; Locatelli, V.; Muccioli, G.; Boeglin, D.; Guerlavais, V.; Fehrentz, J. A.; Martinez, J.; Ghigo, E.; Deghenghi, R.

CORPORATE SOURCE: Department of Internal Medicine, University of Turin, Turin, Italy

SOURCE: Journal of Endocrinological Investigation (2002), 25(8), RC26-RC28

CODEN: JEIIND7; ISSN: 0391-4097

PUBLISHER: Editrice Kurtis s.r.l.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB EP1572 (JMV1843 [Aib-DTrp-DgTrp-CHO]) is a new peptido-mimetic GH secretagogue (GHS) showing binding potency to the GHS-receptor in animal and human tissues similar to that of ghrelin and peptidyl GHS. EP1572 induces marked GH increase after s.c. administration in neonatal rats. Preliminary data in 2 normal young men show that: acute iv EP1572 administration (1.0 .mu.g/kg) induces strong and selective increase of GH levels and single oral EP1572 administration strongly and reproducibly increases GH levels even after a dose as low as 0.06 mg/kg. Thus, EP1572 is a new peptido-mimetic GHS with potent and selective GH-releasing activity.


IT 381231-18-1, EP 1572

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(JMV 1843; EP1572 binding to GH secretagogue receptor and GH secreting activity in male humans and neonatal rats)

RN 381231-18-1 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:923762 HCAPLUS
 DOCUMENT NUMBER: 136:54023
 TITLE: Preparation of peptides as growth hormone
 secretagogues
 INVENTOR(S): Martinez, Jean; Fehrentz, Jean-Alain; Guerlavais,
 Vincent
 PATENT ASSIGNEE(S): Zentaris A.-G., Germany
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096300	A1	20011220	WO 2001-EP6717	20010613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002165343	A1	20021107	US 2001-880498	20010613
PRIORITY APPLN. INFO.:			US 2000-211326P	P 20000613
			US 2000-234928P	P 20000926
OTHER SOURCE(S):		MARPAT 136:54023		
GI				



AB The invention relates to compds. $R_1R_2NC^*HR_3(CH_2)_mCONR_4C^*H(CH_2)_nNHCOR_5$ [* means a carbon atom which, when a chiral carbon atom, has an R or S configuration; one of R_1 and R_3 is H and the other is 3-indolyl or 2-alkyl-3-indolyl; $R_2 = H$, alkyl, aryl, heterocyclyl, cycloalkyl, aryl-,

heterocycl- or cycloalkyl-(CH₂)_n (n = 1 or 2), methylsulfonyl, phenylsulfonyl, acyl group, etc.; R₄ = H, alkyl; R₅ = H, alkyl, aryl-, heterocycl- or cycloalkyl-(CH₂)_n or an amino group; R₆ is as defined for R₁ and R₃, m = 0-2] which are useful for elevating the plasma level of growth hormone in a mammal as well as for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders assocd. with growth hormone secretion deficiency. Thus, compd. I (H-Aib-D-Trp-D-gTrp-CHO) was prepd. and evaluated for growth hormone releasing activity in the infant rat (158.8 +/- 39.4 ng/mL).

IT 381231-18-1P 381231-27-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptides as growth hormone secretagogues)

RN 381231-18-1 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-27-2 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1S)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 381231-62-5P 381231-73-8P 381231-74-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of peptides as growth hormone secretagogues)

RN 381231-62-5 HCAPLUS
 CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 381231-20-5
 CMF C27 H32 N6 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 381231-73-8 HCAPLUS
 CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-21-6
 CMF C27 H32 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 381231-74-9 HCAPLUS


CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-22-7

CMF C28 H34 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:113117 HCAPLUS

DOCUMENT NUMBER: 132:161270

TITLE: Diazaspiro, azepino and azabicyclo therapeutic peptides

INVENTOR(S): Deghenghi, Romano

PATENT ASSIGNEE(S): Switz.

SOURCE: U.S., 6 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6025471	A	20000215	US 1998-89954	19980603
PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 132:161270			US 1998-89954	19980603

AB Peptides are provided which include a spirolactam, bicyclic or tricyclic peptidomimetic unit. The peptides exhibit binding to cardiac tissue and normalize cardiac pressure after administration, as well as diagnostic and therapeutic properties for certain neoplastic tissues. Importantly, these peptides do not release pituitary hormones such as corticotropin and growth hormone and are therefore devoid of certain unwanted side-effects. The peptides preferably have at least one lysine unit and at least one D-2-alkyl-tryptophan unit.

IT 258522-83-7D, derivs. 258522-84-8D, derivs.


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(diazaspiro, azepino and azabicyclo therapeutic peptides)

RN 258522-83-7 HCAPLUS

CN L-Tryptophanamide, 2-methylalanyl-D-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258522-84-8 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-D-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 1-3

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:774900 HCAPLUS

DOCUMENT NUMBER: 138:66879

TITLE: EP1572: A novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man

AUTHOR(S): Broglio, F.; Boutignon, F.; Benso, A.; Gottero, C.; Prodám, F.; Arvat, E.; Ghe, C.; Catapano, F.; Torsello, A.; Locatelli, V.; Muccioli, G.; Boeglin, D.; Guerlavais, V.; Fehrentz, J. A.; Martinez, J.; Ghigo, E.; Deghenghi, R.

CORPORATE SOURCE: Department of Internal Medicine, University of Turin, Turin, Italy

SOURCE: Journal of Endocrinological Investigation (2002), 25(8), RC26-RC28

CODEN: JEIND7; ISSN: 0891-4097

PUBLISHER: Editrice Kurtis s.r.l.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB EP1572 (JMV1843 [Aib-DTrp-DgTrp-CHO]) is a new peptido-mimetic GH secretagogue (GHS) showing binding potency to the GHS-receptor in animal and human tissues similar to that of ghrelin and peptidyl GHS. EP1572 induces marked GH increase after s.c. administration in neonatal rats. Preliminary data in 2 normal young men show that: acute iv EP1572 administration (1.0 .mu.g/kg) induces strong and selective increase of GH levels and single oral EP1572 administration strongly and reproducibly increases GH levels even after a dose as low as 0.06 mg/kg. Thus, EP1572 is a new peptido-mimetic GHS with potent and selective GH-releasing activity.


IT 381231-18-1, EP 1572

RL: BSU (Biological study, unclassified); BIOL (Biological study) (JMV 1843; EP1572 binding to GH secretagogue receptor and GH secreting activity in male humans and neonatal rats)

RN 381231-18-1 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:923762 HCAPLUS

DOCUMENT NUMBER: 136:54023

TITLE: Preparation of peptides as growth hormone secretagogues

INVENTOR(S): Martinez, Jean; Fehrentz, Jean-Alain; Guerlavais, Vincent

PATENT ASSIGNEE(S): Zentaris A.-G., Germany

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096300	A1	20011220	WO 2001-EP6717	20010613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GE, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002165343	A1	20021107	US 2001-880498	20010613
PRIORITY APPLN. INFO.:				
			US 2000-211326P	P 20000613
			US 2000-234928P	P 20000926

OTHER SOURCE(S): MARPAT 136:54023

GI



AB The invention relates to compds. $R_1R_2NC^*HR_3(CH_2)_mCONR_4C^*H(CH_2R_6)NHCOR_5$ [* means a carbon atom which, when a chiral carbon atom, has an R or S configuration; one of R_1 and R_3 is H and the other is 3-indolyl or 2-alkyl-3-indolyl; R_2 = H, alkyl, aryl, heterocyclyl, cycloalkyl, aryl-, heterocyclyl- or cycloalkyl- $(CH_2)_n$ (n = 1 or 2), methylsulfonyl,

phenylsulfonyl, acyl group, etc.; R4 = H, alkyl; R5 = H, alkyl, aryl-, heterocycl- or cycloalkyl-(CH₂)_n or an amino group; R6 is as defined for R1 and R3, m = 0-2] which are useful for elevating the plasma level of growth hormone in a mammal as well as for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders assocd. with growth hormone secretion deficiency. Thus, compd. I (H-Aib-D-Trp-D-gTrp-CHO) was prepd. and evaluated for growth hormone releasing activity in the infant rat (158.8 \pm 39.4 ng/mL).

IT **381231-18-1P 381231-27-2P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptides as growth hormone secretagogues)

RN 381231-18-1 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-27-2 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1S)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **381231-62-5P 381231-73-8P 381231-74-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of peptides as growth hormone secretagogues)

RN 381231-62-5 HCAPLUS


CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-20-5

CMF C27 H32 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 381231-73-8 HCAPLUS


CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-21-6

CMF C27 H32 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 381231-74-9 HCAPLUS


CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-22-7

CMF C28 H34 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:113117 HCAPLUS

DOCUMENT NUMBER: 132:161270

TITLE: Diazaspiro, azepino and azabicyclo therapeutic peptides

INVENTOR(S): Deghenghi, Romano

PATENT ASSIGNEE(S): Switz.

SOURCE: U.S., 6 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6025471	A	20000215	US 1998-89954	19980603
PRIORITY APPLN. INFO.:			US 1998-89954	19980603
OTHER SOURCE(S): MARPAT 132:161270				

AB Peptides are provided which include a spirolactam, bicyclic or tricyclic peptidomimetic unit. The peptides exhibit binding to cardiac tissue and normalize cardiac pressure after administration, as well as diagnostic and therapeutic properties for certain neoplastic tissues. Importantly, these peptides do not release pituitary hormones such as corticotropin and growth hormone and are therefore devoid of certain unwanted side-effects. The peptides preferably have at least one lysine unit and at least one D-2-alkyl-tryptophan unit.

IT 258522-83-7D, derivs. 258522-84-8D, derivs.

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(diazaspiro, azepino and azabicyclo therapeutic peptides)

RN 258522-83-7 HCAPLUS

CN L-Tryptophanamide, 2-methylalanyl-D-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> d ibib abs hitstr 1-3

L22 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:692571 HCAPLUS

TITLE: A novel series of growth hormone secretagogues

AUTHOR(S): **Guerlavais, Vincent**; Boeglin, Damien;
Fehrentz, Jean-Alain; Deghenghi, Romano;
Locatelli, Vittorio; Muccioli, Giampiero;
Martinez, Jean

CORPORATE SOURCE: Laboratoire des Aminoacides, Peptides et Proteines,
UMR 5810, Faculte de Pharmacie, Universitاس
Montpellier I et II, Montpellier, 34060, Fr.

SOURCE: Peptides: The Wave of the Future, Proceedings of the
Second International and the Seventeenth American
Peptide Symposium, San Diego, CA, United States, June
9-14, 2001 (2001), 748-749. Editor(s): Lebl, Michال;
Houghten, Richard A. American Peptide Society: San
Diego, Calif.
CODEN: 69DBAL; ISBN: 0-9715560-0-8

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A new class of orally bioavailable pseudotripeptide analogs of EP-51389
was synthesized and biol. evaluated. Several compds. were found to be
efficacious in elevating plasma growth hormone in the rat. The best
compds. showed similar and even higher activity than Hexarelin when tested
on dogs by oral route. Growth hormone secretagogues are currently
undergoing clin. evaluation as alternatives to growth hormone replacement
therapy. Some of the compds. have been selected as candidates for further
development.

IT INDEXING IN PROGRESS

IT **9002-72-6**, Growth hormone

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hexarelin and EP-51389 pseudotripeptide analogs as growth hormone
secretagogues)

RN 9002-72-6 HCAPLUS

CN Somatotropin (9CI) (CA INDEX NAME)

IT **192387-85-2D**, EP-51389, analogs


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(hexarelin and EP-51389 pseudotripeptide analogs as growth hormone
secretagogues)

RN 192387-85-2 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-2-methyl-D-tryptophyl-2-methyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:923762 HCAPLUS

DOCUMENT NUMBER: 136:54023

TITLE: Preparation of peptides as growth hormone secretagogues

INVENTOR(S): Martinez, Jean; Fehrentz, Jean-Alain
; Guerlavais, Vincent

PATENT ASSIGNEE(S): Zentaris A.-G., Germany

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096300	A1	20011220	WO 2001-EP6717	20010613

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002165343	A1	20021107	US 2001-880498	20010613
---------------	----	----------	----------------	----------


PRIORITY APPLN. INFO.:

US 2000-211326P P 20000613

US 2000-234928P P 20000926

OTHER SOURCE(S): MARPAT 136:54023

GI




AB The invention relates to compds. $R_1R_2NC^*HR_3(CH_2)_mCONR_4C^*H(CH_2R_6)NHCOR_5$ [* means a carbon atom which, when a chiral carbon atom, has an R or S configuration; one of R_1 and R_3 is H and the other is 3-indolyl or 2-alkyl-3-indolyl; R_2 = H, alkyl, aryl, heterocyclyl, cycloalkyl, aryl-, heterocyclyl- or cycloalkyl- $(CH_2)_n$ (n = 1 or 2), methylsulfonyl, phenylsulfonyl, acyl group, etc.; R_4 = H, alkyl; R_5 = H, alkyl, aryl-, heterocyclyl- or cycloalkyl- $(CH_2)_n$ or an amino group; R_6 is as defined for R_1 and R_3 , m = 0-2] which are useful for elevating the plasma level of growth hormone in a mammal as well as for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders assocd. with growth hormone secretion deficiency. Thus, compd. I (H-Aib-D-Trp-D-gTrp-CHO) was prepd. and evaluated for growth hormone releasing activity in the infant rat (158.8 \pm 39.4 ng/mL).

IT 9002-72-6, Growth hormone
 RL: BCP (Biochemical process); BIOL (Biological study); PROC (Process)
 (prepn. of peptides as growth hormone secretagogues)
 RN 9002-72-6 HCAPLUS
 CN Somatotropin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 381231-18-1P 381231-19-2P 381231-20-5P
 381231-21-6P 381231-22-7P 381231-23-8P
 381231-24-9P 381231-25-0P 381231-26-1P
 381231-27-2P 381231-28-3P 381231-29-4P
 381231-30-7P 381231-31-8P 381231-32-9P
 381231-33-0P 381231-34-1P 381231-35-2P
 381231-36-3P 381231-37-4P 381231-38-5P
 381231-39-6P 381231-40-9P 381231-41-0P
 381231-42-1P 381231-43-2P 381231-44-3P
 381231-45-4P 381231-46-5P 381231-47-6P
 381231-48-7P 381231-49-8P 381231-50-1P
 381231-51-2P 381231-52-3P 381231-53-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of peptides as growth hormone secretagogues)
 RN 381231-18-1 HCAPLUS
 CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-19-2 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(2-methyl-1H-indol-3-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-20-5 HCAPLUS

CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381231-21-6 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-

yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-22-7 HCAPLUS

CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-23-8 HCAPLUS


CN 1H-Indole-3-propanamide, .alpha.-[[(4-amino-4-piperidinyl)carbonyl]amino]-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381231-24-9 HCAPLUS
 CN 1H-Indole-3-propanamide, N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-
 .alpha.-[[4-amino-4-piperidinyl]carbonyl]amino]-, (.alpha.R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 381231-25-0 HCAPLUS
 CN 1H-Indole-3-propanamide, N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-
 .alpha.-[[4-piperidinylcarbonyl]amino]-, (.alpha.R)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 381231-26-1 HCAPLUS
 CN 1H-Indole-3-propanamide, N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-
 .alpha.-[[4-piperidinylcarbonyl]amino]-, (.alpha.R)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 381231-27-2 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1S)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-28-3 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1S)-2-(1H-indol-3-yl)-1-[(1-oxopropyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-29-4 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1S)-2-(1H-indol-3-yl)-1-[(4-piperidinylcarbonyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-30-7 HCAPLUS

CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-2-(1H-indol-3-yl)-1-[(4-piperidinylcarbonyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-31-8 HCAPLUS

CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-32-9 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-33-0 HCAPLUS

CN D-Alaninamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1-naphthalenyl)ethyl]-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-34-1 HCAPLUS

CN D-Alaninamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(2-naphthalenyl)ethyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-35-2 HCAPLUS

CN D-Alaninamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381231-36-3 HCAPLUS

CN D-Alaninamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)

yl)ethyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-37-4 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-38-5 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-39-6 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-2-(2,3-dihydro-1H-indol-3-yl)-1-(formylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-40-9 HCAPLUS

CN D-Alaninamide, 2-methylalanyl-3-(2,3-dihydro-1H-indol-3-yl)-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-41-0 HCAPLUS

CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(2,3-dihydro-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-42-1 HCAPLUS

CN D-Alaninamide, N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-3-(2,3-dihydro-1H-indol-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-43-2 HCAPLUS

CN D-Tryptophanamide, N,N,2-trimethylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 381231-44-3 HCAPLUS

CN D-Tryptophanamide, N,N,2-trimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-

indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-45-4 HCAPLUS

CN 1H-Indole-3-propanamide, .alpha.-[[[(1-aminocyclopropyl)carbonyl]amino]-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-46-5 HCAPLUS

CN 1H-Indole-3-propanamide, .alpha.-[[[(1-aminocyclopentyl)carbonyl]amino]-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-47-6 HCAPLUS

CN 1H-Indole-3-propanamide, .alpha.-[[(1-aminocyclohexyl)carbonyl]amino]-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-48-7 HCAPLUS

CN D-Tryptophanamide, 2-propylnorvalyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-49-8 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1S)-1-[[(ethylamino) carbonyl] amino]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-50-1 HCAPLUS

CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1S)-1-[[(ethylamino) carbonyl] amino]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-51-2 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-52-3 HCAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1-methyl-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-53-4 HCAPLUS


CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1-methyl-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 2279-15-4 33104-36-8, 2,4,5-Trichlorophenyl formate
 146000-39-7 148928-15-8 189321-65-1
 381231-60-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of peptides as growth hormone secretagogues)
 RN 2279-15-4 HCAPLUS
 CN D-Tryptophan, N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 33104-36-8 HCAPLUS
 CN Phenol, 2,4,5-trichloro-, formate (8CI, 9CI) (CA INDEX NAME)



RN 146000-39-7 HCAPLUS
 CN Alanine, N-[(1,1-dimethylethoxy)carbonyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 148928-15-8 HCAPLUS
 CN 1,4-Piperidinedicarboxylic acid, 1-(9H-fluoren-9-ylmethyl) ester (9CI)
 (CA INDEX NAME)



RN 189321-65-1 HCAPLUS

CN 1,4-Piperidinedicarboxylic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 381231-60-3 HCAPLUS


CN 1H-Indole-3-propanamide, .alpha.-amino-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, (.alpha.R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-59-0

CMF C22 H23 N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 168110-39-2P 381231-54-5P 381231-55-6P
 381231-56-7P 381231-57-8P 381231-58-9P
 381231-61-4P 381231-62-5P 381231-63-6P
 381231-65-8P 381231-66-9P 381231-67-0P
 381231-68-1P 381231-69-2P 381231-70-5P
 381231-72-7P 381231-73-8P 381231-74-9P
 381231-75-0P 381231-76-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(prepn. of peptides as growth hormone secretagogues)

RN 168110-39-2 HCAPLUS

CN Carbamic acid, [(1R)-2-amino-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-,
 phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-54-5 HCAPLUS

CN D-Tryptophanamide, N-[(1,1-dimethylethoxy)carbonyl]-D-tryptophyl- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-55-6 HCAPLUS

CN D-Tryptophanamide, N,1-bis[(1,1-dimethylethoxy)carbonyl]-D-tryptophyl-1-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-56-7 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[(2R)-2-amino-2-[[[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[1-[(1,1-dimethylethoxy)carbonyl]-1H-indol-3-yl]-1-oxopropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-57-8 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[[(1R)-2-[1-[(1,1-dimethylethoxy)carbonyl]-1H-indol-3-yl]-1-(formylamino)ethyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-58-9 HCAPLUS

CN D-Tryptophanamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-61-4 HCAPLUS

CN D-Tryptophanamide, N-[(1,1-dimethylethoxy)carbonyl]-N,2-dimethylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381231-62-5 HCAPLUS


CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-20-5

CMF C27 H32 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 381231-63-6 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[(2R)-2-(acetylamino)-2-[[(2R)-2-[[(1,1-dimethylethoxy) carbonyl] amino]-3-[1-[(1,1-dimethylethoxy) carbonyl]-1H-indol-3-yl]-1-oxopropyl] amino] ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381231-65-8 HCAPLUS


CN 1H-Indole-3-propanamide, N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-
.alpha.-amino-, (.alpha.R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-64-7

CMF C23 H25 N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 381231-66-9 HCAPLUS

CN D-Tryptophanamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(1R)-
1-(acetylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-67-0 HCAPLUS

CN D-Tryptophanamide, N-[(1,1-dimethylethoxy)carbonyl]-N,2-dimethylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-68-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-[[[(1R)-2-[[[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-69-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(1R)-2-[[[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 381231-70-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(1R)-2-[[[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]-9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381231-72-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(1R)-2-[[[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]carbonyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381231-73-8 HCAPLUS


CN D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-21-6

CMF C27 H32 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 381231-74-9 HCAPLUS


CN D-Tryptophanamide, N,2-dimethylalanyl-N-[(1R)-1-(acetamino)-2-(1H-indol-3-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-22-7

CMF C28 H34 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 381231-75-0 HCAPLUS


CN 1H-Indole-3-propanamide, .alpha.-[[(4-amino-4-piperidinyl)carbonyl]amino]-
N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-, (.alpha.R)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-23-8

CMF C28 H33 N7 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 381231-76-1 HCAPLUS


CN 1H-Indole-3-propanamide, N-[(1R)-1-(acetylamino)-2-(1H-indol-3-yl)ethyl]-
.alpha.-[[(4-amino-4-piperidinyl)carbonyl]amino]-, (.alpha.R)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 381231-24-9

CMF C29 H35 N7 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:625044 HCAPLUS

DOCUMENT NUMBER: 129:331028

TITLE: Synthesis of peptide aldehydes on solid support using ozonolysis

AUTHOR(S): Paris, Marielle; Heitz, Annie; **Guerlavais, Vincent**; Cristau, Michele; **Fehrentz, Jean-Alain**; **Martinez, Jean**

CORPORATE SOURCE: Lab. Amino-acides, Peptides Proteines, Univ. Montpellier I, Montpellier, 34060, Fr.

SOURCE: Tetrahedron Letters (1998), 39(40), 7287-7290

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new strategy for the synthesis of peptide aldehydes on solid support is presented. Rxn of a N-protected .alpha.-amino aldehyde with MBHA-supported Wittig-Horner reagent yielded resin-linked .alpha.-.beta.-unsatd. .delta.-amino deriv. After elongation of the peptide chain, ozonolysis produced fairly pure C-terminal peptide

aldehydes in good yield.

IT 215111-41-4P


RL: BYP (Byproduct); PREP (Preparation)

(synthesis of peptide aldehydes on solid support using ozonolysis)

RN 215111-41-4 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[(1R)-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 79-11-8, reactions 603-35-0, Triphenylphosphine,


reactions 3095-95-2 47507-41-5 79069-50-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of peptide aldehydes on solid support using ozonolysis)


RN 79-11-8 HCAPLUS

CN Acetic acid, chloro- (8CI, 9CI) (CA INDEX NAME)




RN 603-35-0 HCAPLUS

CN Phosphine, triphenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3095-95-2 HCAPLUS


CN Acetic acid, (diethoxyphosphinyl)- (9CI) (CA INDEX NAME)



RN 47507-41-5 HCAPLUS

CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 79069-50-4 HCAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 172299-76-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of peptide aldehydes on solid support using ozonolysis)

RN 172299-76-2 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT